U.S. COMPANY FILING
ASTRAZENECA PLC — Form 20-F filed 2026-02-24
Filing text preview
AstraZeneca's 2025 annual report shows revenue growth, but highlights risks from litigation, restructuring, and impairments. The company terminated its ADR program and directly listed on NYSE on Feb 2, 2026. Dividends increased to $3.13 per share.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record